Opus Genetics, Inc. (IRD) - Dilution Analysis

10-Q filing | 86.9M shares outstanding

S-3 filing: This prospectus relates to the resale or other disposition, from time to time, by the selling stockholders named in this prospectus of up to 7,374,632 shares of our common stock, par value $0.0001 per share, issuable upon the conversion of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.0001.

10-K filing | 71.1M shares outstanding

8-K filing: Opus Genetics, Inc. entered into a securities purchase agreement for a registered direct offering of 3,827,751 shares of common stock and pre-funded warrants to purchase 7,177,033 shares, with gross proceeds expected to be approximately $23.0 million. ($23.0M proceeds)

10-Q filing | 59.7M shares outstanding

S-3/A filing: This S-3/A filing relates to the resale by selling securityholders of up to 19,382,437 shares of common stock in connection with the acquisition of former Opus Genetics Inc.

10-K filing | 45.5M shares outstanding

8-K filing: Opus Genetics, Inc. completed a private placement of common stock and warrants with Dr. George Magrath and Cam Gallagher and a public offering of common stock, pre-funded warrants and warrants. ($40.0M proceeds)

S-3 filing: The filing relates to the issuance of up to 19,382,437 shares of common stock in connection with the acquisition of former Opus Genetics Inc.

10-Q filing | 31.6M shares outstanding

10-Q filing | 25.8M shares outstanding

10-Q filing | 24.5M shares outstanding

10-K filing | 24.8M shares outstanding

S-3 filing: The company may offer and sell up to $175,000,000 of any combination of common stock, preferred stock, debt securities and/or warrants.

10-Q filing | 22.4M shares outstanding

8-K filing: The Board adopted the First Amendment to the Company's Inducement Plan, increasing the aggregate number of shares of common stock that may be issued pursuant to equity incentive awards under the Inducement Plan by 2,000,000 shares for a total of 2,325,258 shares of common stock. Effective as of November 15, 2023, the document outlines the composition of the committees of the Board.

8-K filing: Ocuphire Pharma, Inc. entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC, allowing the Company to sell up to $50,000,000 of its common stock over a 30-month term, and issued 246,792 commitment shares to Lincoln Park. ($0.04M proceeds)

10-Q filing | 21.0M shares outstanding

10-Q filing | 20.9M shares outstanding

10-K filing | 20.6M shares outstanding

10-Q filing | 20.5M shares outstanding

10-Q filing | 19.5M shares outstanding

10-Q filing | 18.9M shares outstanding

10-K filing | 19.0M shares outstanding

10-Q filing | 16.9M shares outstanding

10-Q filing | 16.9M shares outstanding

8-K filing: Ocuphire Pharma, Inc. entered into a License Agreement with Processa Pharmaceuticals, Inc. where Ocuphire granted Processa an exclusive license to develop, manufacture and commercialize RX-3117 globally, excluding China, in exchange for 44,689 shares of Processa common stock and a $200,000 cash payment.

8-K filing: Ocuphire Pharma, Inc. entered into a registered direct offering, selling 3,076,923 shares of common stock and warrants to purchase 1,538,461 shares at $4.875 per share and 0.50 warrants, for gross proceeds of approximately $15,000,000. ($15.0M proceeds)

10-Q filing | 10.9M shares outstanding

10-K filing | 2.9M shares outstanding

S-3/A filing: This is an S-3/A filing to replace Exhibit 5.1 to the Registration Statement and does not modify any provision of the prospectus.

S-3 filing: The filing is for a shelf offering of common stock, preferred stock, and debt securities, as well as an offering of common stock by selling stockholders.

8-K filing: Ocuphire Pharma, Inc. entered into Waiver Agreements with Holders to waive certain rights, finalize the exercise price and number of Series A Warrants and Series B Warrants, eliminate certain financing restrictions, extend the term of certain leak-out agreements, and grant certain registration rights for the shares underlying the Warrants.

8-K filing: Ocuphire Pharma, Inc. issued Series A Warrants exercisable for 5,665,838 shares at $4.4795 per share and Series B Warrants exercisable for 665,837 shares at $0.0001 per share on November 19, 2020, pursuant to the Pre-Merger Financing.

8-K filing: Ocuphire Pharma, Inc. completed a 1-for-4 reverse stock split on November 5, 2020, and also completed a pre-merger financing of approximately $21,150,000 involving the issuance of Ocuphire common stock that converts into approximately 1,249,996 shares of common stock and the deposit of additional shares into escrow that convert into approximately 3,749,992 shares of Common Stock after the merger, along with warrants to purchase Common Stock. ($21.15M proceeds)

10-Q filing | 4.5M shares outstanding

8-K filing: Rexahn Pharmaceuticals, Inc. entered into Warrant Exchange Agreements with Empery Asset Master, Ltd., Empery Tax Efficient, LP, and Empery Tax Efficient II, LP, issuing an aggregate of 16,324, 9,081 and 30,774 shares of Common Stock to EAM, ETE and ETE II, respectively, in exchange for the surrender and cancellation of warrants.

8-K filing: Rexahn Pharmaceuticals, Inc. entered into a Warrant Exchange Agreement with Anson Investments Master Fund LP, issuing 192,878 shares of Common Stock in exchange for the surrender and cancellation of warrants to purchase 62,500, 44,192, 160,257 and 145,502 shares of common stock.

10-Q filing | 4.2M shares outstanding

8-K filing: Rexahn Pharmaceuticals, Inc. entered into a Warrant Exchange Agreement with Armistice Capital Master Fund Ltd. On August 3, 2020, the Company is issuing to Armistice an aggregate of 215,000 shares of Common Stock in exchange for the surrender and cancellation of the Warrants.

10-Q filing | 4.0M shares outstanding

10-K filing | 4.0M shares outstanding